Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy.
作者信息
Chiricozzi Andrea, Di Nardo Lucia, Talamonti Marina, Galluzzo Marco, De Simone Clara, Fabbrocini Gabriella, Marzano Angelo Valerio, Girolomoni Giampiero, Offidani Annamaria, Rossi Maria Teresa, Bianchi Luca, Cristaudo Antonio, Fierro Maria Teresa, Stingeni Luca, Pellacani Giovanni, Argenziano Giuseppe, Patrizi Annalisa, Pigatto Paolo, Romanelli Marco, Savoia Paola, Rubegni Pietro, Foti Caterina, Milanesi Nicola, Belloni Fortina Anna, Bongiorno Maria Rita, Grieco Teresa, Di Nuzzo Sergio, Fargnoli Maria Concetta, Carugno Andrea, Motolese Alberico, Rongioletti Franco, Amerio Paolo, Balestri Riccardo, Potenza Concetta, Micali Giuseppe, Patruno Cataldo, Zalaudek Iris, Lombardo Maurizio, Feliciani Claudio, Antonelli Flaminia, Ferrucci Silvia Mariel, Guarneri Fabrizio, Peris Ketty
出版信息
Dermatitis. 2022;33(3):e25-e29. doi: 10.1097/DER.0000000000000814. Epub 2021 Dec 10.
Abstract
摘要
相似文献
1
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy.因与 COVID-19 相关原因停用度普利尤单抗单药治疗的患者与继续使用度普利尤单抗治疗的患者表现出相似的病程。
Dermatitis. 2022;33(3):e25-e29. doi: 10.1097/DER.0000000000000814. Epub 2021 Dec 10.
2
Atopic dermatitis patient perspectives on dupilumab therapy during the COVID-19 pandemic: an international survey study.特应性皮炎患者对COVID-19大流行期间度普利尤单抗治疗的看法：一项国际调查研究。
Dermatol Online J. 2021 Nov 15;27(11). doi: 10.5070/D3271156095.
3
Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.真实世界中成人特应性皮炎患者接受度普利尤单抗治疗的经验：患者病历的回顾性分析。
Int J Dermatol. 2020 Feb;59(2):253-256. doi: 10.1111/ijd.14573. Epub 2019 Jul 8.
4
Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.COVID-19 大流行和封锁对度普利尤单抗治疗的临床反应和未感染特应性患者心理状况的影响。
Eur J Dermatol. 2021 Dec 1;31(6):736-740. doi: 10.1684/ejd.2021.4135.
5
Dupilumab for the Treatment of Atopic Dermatitis.度普利尤单抗治疗特应性皮炎
Actas Dermosifiliogr (Engl Ed). 2018 Apr;109(3):230-240. doi: 10.1016/j.ad.2017.10.012. Epub 2018 Feb 13.
6
Dupilumab facial redness: histologic characterization on a series of four cases.度匹鲁单抗致面部发红：4 例系列病例的组织学特征。
Immunotherapy. 2022 Mar;14(4):183-188. doi: 10.2217/imt-2021-0122. Epub 2021 Dec 22.
7
Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.度普利尤单抗在中度至重度特应性皮炎成年患者中的实际疗效和安全性。
Dermatol Ther. 2022 Jan;35(1):e15192. doi: 10.1111/dth.15192. Epub 2021 Nov 15.
8
Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.度普利尤单抗治疗特应性皮炎患者的长期疗效和安全性：荷兰特应性皮炎治疗登记研究（TREAT NL）的结果。
J Am Acad Dermatol. 2020 Nov;83(5):1375-1384. doi: 10.1016/j.jaad.2020.05.128. Epub 2020 May 30.
9
Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature.达必妥治疗中重度特应性皮炎伴斑秃患者 1 例并文献复习
Australas J Dermatol. 2020 May;61(2):e223-e225. doi: 10.1111/ajd.13208. Epub 2019 Nov 25.
10
[Psoriasis in dupilumab-treated atopic dermatitis].[度普利尤单抗治疗特应性皮炎中的银屑病]
Hautarzt. 2020 May;71(5):383-386. doi: 10.1007/s00105-020-04565-8.
引用本文的文献
1
Drug Survival, Retention, and Persistence of Dupilumab in Adults and Adolescents with Atopic Dermatitis: A Narrative Literature Review.度普利尤单抗在成人和青少年特应性皮炎患者中的药物生存、留存及持续性：一项叙述性文献综述
Adv Ther. 2025 Jan;42(1):94-105. doi: 10.1007/s12325-024-03052-z. Epub 2024 Nov 15.
2
Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review.2019年冠状病毒病大流行对特应性皮炎和食物过敏的成人及儿童的影响：系统评价
J Allergy Clin Immunol Glob. 2023 Oct 18;3(1):100181. doi: 10.1016/j.jacig.2023.100181. eCollection 2024 Feb.
本文引用的文献
1
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.青少年特应性皮炎：在意大利新冠疫情期间16周真实临床实践中使用度普利尤单抗的有效性和安全性
Dermatol Ther. 2021 Sep;34(5):e15035. doi: 10.1111/dth.15035. Epub 2021 Jun 25.
2
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.意大利 COVID-19 大流行期间接受全身治疗的特应性皮炎患者的管理：来自 DA-COVID-19 登记处的数据。
Allergy. 2021 Jun;76(6):1813-1824. doi: 10.1111/all.14767. Epub 2021 Mar 9.
3
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.成功联合全身用药物治疗对度普利尤单抗治疗抵抗的特应性皮炎。
Dermatology. 2021;237(4):535-541. doi: 10.1159/000512890. Epub 2021 Jan 21.
4
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.在新冠疫情期间使用度普利尤单抗治疗重度特应性皮炎成年患者的管理：一项单中心真实世界经验
Dermatol Ther. 2020 Jul;33(4):e13765. doi: 10.1111/dth.13765. Epub 2020 Jun 30.
5
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.度普利尤单抗在接受 3 期开放标签扩展研究的中重度特应性皮炎患者中显示出长期安全性和疗效。
J Am Acad Dermatol. 2020 Feb;82(2):377-388. doi: 10.1016/j.jaad.2019.07.074. Epub 2019 Jul 30.
Zotero 插件